Sugi Predict

Sugi Predict / Targets / CACNG1

CACNG1

Voltage-dependent calcium channel gamma-1 sub · Q06432 · CACNG1 on Sugi Atlas →

6,532 patent compounds predicted against CACNG1, 2,798 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

CompoundConfidenceSupporting neighbours
SCHEMBL116362 SCHEMBL116362 0.45 11/20
SCHEMBL6121858 SCHEMBL6121858 0.52 9/20
SCHEMBL2585915 SCHEMBL2585915 0.51 8/20
SCHEMBL3354274 SCHEMBL3354274 0.62 7/20
SCHEMBL3357851 SCHEMBL3357851 0.54 7/20
SCHEMBL4750473 SCHEMBL4750473 0.52 7/20
SCHEMBL3350921 SCHEMBL3350921 0.49 7/20
SCHEMBL619154 SCHEMBL619154 0.41 7/20
SCHEMBL620978 SCHEMBL620978 0.40 7/20
SCHEMBL621013 SCHEMBL621013 0.40 7/20
SCHEMBL5428566 SCHEMBL5428566 0.52 6/20
SCHEMBL621555 SCHEMBL621555 0.39 6/20
SCHEMBL617973 SCHEMBL617973 0.38 6/20
SCHEMBL4405461 SCHEMBL4405461 0.55 5/20
SCHEMBL4399845 SCHEMBL4399845 0.54 5/20
SCHEMBL4967687 SCHEMBL4967687 0.51 5/20
SCHEMBL1810921 SCHEMBL1810921 0.51 5/20
SCHEMBL4399843 SCHEMBL4399843 0.50 5/20
SCHEMBL3477582 SCHEMBL3477582 0.47 5/20
SCHEMBL3353571 SCHEMBL3353571 0.47 5/20

Clinical trials — most relevant to CACNG1 by text similarity (a relevance ranking, not an exhaustive list)

TrialPhaseStatus
The Effect of Pregabalin and Etoricoxib on Pain Alone Versus in Combination PHASE4UNKNOWN
Efficacy and Safety of Mirogabalin in Diabetic Peripheral Neuropathic Pain PHASE4RECRUITING
Comparative Study of Dietary and Immunological Management of Refractory Epilepsy in Children PHASE4UNKNOWN
Multimodal Versus Opioid aNalgesia in carDiAc Surgery PHASE4COMPLETED
Role of Intralipid in Management of Organophosphorus Poisoning PHASE2/PHASE3WITHDRAWN
Dronabinol in Trichotillomania and Other Body Focused Repetitive Behaviors PHASE2/PHASE3COMPLETED
The Re-Prosper HF Study PHASE2/PHASE3COMPLETED
Effect of Oral Pregabalin on Spinal Neurotransmitters in Patients Undergoing Knee Replacement PHASE3COMPLETED
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients PHASE2WITHDRAWN
A Phase I/II, First-In-Human Trial to Evaluate the Safety, Tolerability, and Pharmacokinetic Activity to Prevent or Treat Neuropsychiatric Symptoms in Pediatric Subjects With Timothy Syndrome PHASE1/PHASE2NOT_YET_RECRUITING
Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Trauma Patients PHASE2WITHDRAWN
Population Pharmacokinetic-pharmacodynamic (PK-PD) Modeling of Co-administered Gabapentin in Neuropathic Pain PHASE2COMPLETED
4-Aminopyridine in Episodic Ataxia Type 2 PHASE2WITHDRAWN
Safety and Efficacy of MEM 1003 Versus Placebo in Patients With Mild to Moderate Alzheimer's Disease PHASE2COMPLETED
Effect of Lidocaine Transdermal Patch as Add-On Therapy in Treatment of Oxaliplatin Induced Peripheral Neuropathy in Colorectal Cancer Patients PHASE2UNKNOWN
ST-segment Elevation as an AF Endophenotype nanCOMPLETED
Molecular and Cellular Characterization of Cardiac Tissue in Postnatal Development nanRECRUITING
Factors Affecting Salt Intake in Young Adults nanUNKNOWN
Sodium Channel Splicing in Heart Failure Trial (SOCS-HEFT) Prospective Study nanUNKNOWN
Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases nanUNKNOWN
Genetic Determinants of Sudden Cardiac Death nanCOMPLETED
Sodium Channel Splicing in Heart Failure Trial nanCOMPLETED
Gene-STEPS: Shortening Time of Evaluation in Paediatric Epilepsy Services nanUNKNOWN
Pregabalin Phonophoresis and MET for Knee Osteoarthritis nanRECRUITING
Evaluation of A Clinical Diagnostic Test for CRDS nanRECRUITING
Manganese-Enhanced Magnetic Resonance Imaging (MEMRI) in Ischaemic, Inflammatory and Takotsubo Cardiomyopathy (MEMORY) nanCOMPLETED
The Prevalence of RYR1-related Disease nanNOT_YET_RECRUITING
Rolandic Epilepsy Genomewide Association International Study nanCOMPLETED
Urine Concentration of S100B in Extremely Premature Infants nanCOMPLETED
Pharmacogenetics and Cardiovascular Events nanCOMPLETED

Related proteins — ESM-2 sequence neighbours (a CACNG1 binder may also engage these)

ProteinNameSimilarity
P19518 — 0.996 P19518 →
Q2MJQ7 — 0.993 Q2MJQ7 →
Q08DE1 — 0.990 Q08DE1 →
O70578 — 0.986 O70578 →
P97707 — 0.980 P97707 →
Q9NY35 — 0.971 Q9NY35 →
Q5RDV7 — 0.971 Q5RDV7 →
Q9D563 — 0.968 Q9D563 →
A0A1D5NY17 — 0.967 A0A1D5NY17 →
Q4R4Z3 — 0.965 Q4R4Z3 →
Q9CQX5 — 0.964 Q9CQX5 →
Q8VHW7 — 0.964 Q8VHW7 →
Q6ZP80 — 0.963 Q6ZP80 →
Q9XT98 — 0.963 Q9XT98 →
A4IF75 — 0.962 A4IF75 →
Q9CZ16 — 0.961 Q9CZ16 →
Q08CE6 — 0.960 Q08CE6 →
Q68FV0 — 0.959 Q68FV0 →
CACNG5 Voltage-dependent calcium channel gamma-5 sub 0.959 landscape →
Q8VHW3 — 0.959 Q8VHW3 →
CACNG6 Voltage-dependent calcium channel gamma-6 sub 0.958 landscape →
Q8VHW4 — 0.957 Q8VHW4 →
B2RVY9 — 0.956 B2RVY9 →
Q8VHW8 — 0.955 Q8VHW8 →
B3SHH9 — 0.955 B3SHH9 →
Q8NBL3 — 0.953 Q8NBL3 →
Q5XGU1 — 0.953 Q5XGU1 →
Q91Y55 — 0.951 Q91Y55 →
Q925N4 — 0.948 Q925N4 →
Q9Y5I7 — 0.947 Q9Y5I7 →